



FOR IMMEDIATE RELEASE

Contact:

Adam Rubenstein

arubenstein@rnaventures.com

(303) 902-4413

<http://OnBioVC.com>

OnBioVC RELEASES 4Q & 2011 TREND ANALYSIS YEAR-IN-REVIEW REPORT

Life Science Investments Accelerate into the Final Twelve Weeks of 2011

Boulder, CO (PR Web) February 21, 2012 – OnBioVC the industry leader in organizing and reporting life science private venture financings, today announced the release of its 2011 Trend Analysis. The 4Q11 OnBioVC Trend Analysis tracked, in aggregate, 93 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling \$1,662.8M, compared to 4Q10 OnBioVC data, this investment activity represents an increase in the number of quarter-over-quarter financings by 37 (93 v. 56) and an increase in quarter-over-quarter total invested capital of \$816.6M (\$1,662.8M v. \$846.2M). 2011 likewise yielded year-over-year increases v. 2010 in total deals (305 v. 281) and invested capital (\$6,071.2 v. \$5,190.5). 4Q11 also provided the largest number of Series A financings in fifteen quarters of OnBioVC data tracking, where 37 first-time institutional financings raised \$483.4M.

In addition to an increase in the volume of life science risk capital being put to work the year observed considerable activity in the formation of fresh funds, where no less than eight venture, corporate and philanthropic funds were launched or closed, accounting for over \$1.2 billion designed to be deployed into therapeutic, diagnostic, device and health-IT newcos.

M&A activity was robust in the final quarter where thirteen transactions greater than \$50M tallied \$19.3 billion, however the cohort was skewed by Foster City, CA-based Gilead's acquisition of Princeton, New Jersey-based Pharmasset for \$137 per share or approximately \$11 billion.

“As 2011 wound down an acceleration of all aspects of life science financing activity yielded a bullish signal from both the private and public markets,” said Adam Rubenstein, Managing Editor of OnBioVC. “We are pleased to present details of the 2011 life science investment landscape which saw robust participation in Series A financings, new fund creation, M&A and the number of IPO filings, all of which are presented in the 2011 OnBioVC Trend Analysis Year-in-Review report.”

About OnBioVC

Based in Boulder, CO, OnBioVC, an Indicium Data Company, provides timely coverage and comprehensive analysis of global life science private and public capital investment, M&A and IPO activity. Quarterly published reports parse out transactional activity of private therapeutic, diagnostic, medical device, medical-IT and biofuel companies. The companion site, OnBioVC.com, provides deal data that is searchable by aggregate dollars raised via round, region, state, industry sector, indications and technologies as well as tagging the venture funds participating in individual financings. For more information please visit <http://OnBioVC.com>.

###